An evolutionary approach to cancer chemotherapy scheduling

In this paper, we investigate the employment of evolutionary algorithms as a search mechanism in a decision support system for designing chemotherapy schedules. Chemotherapy involves using powerful anti-cancer drugs to help eliminate cancerous cells and cure the condition. It is given in cycles of treatment alternating with rest periods to allow the body to recover from toxic side-effects. The number and duration of these cycles would depend on many factors, and the oncologist would schedule a treatment for each patient’s condition. The design of a chemotherapy schedule can be formulated as an optimal control problem; using an underlying mathematical model of tumour growth (that considers interactions with the immune system and multiple applications of a cycle-phase-specific drug), the objective is to find effective drug schedules that help eradicate the tumour while maintaining the patient health’s above an acceptable level. A detailed study on the effects of different objective functions, in the quality and diversity of the solutions, was performed. A term that keeps at a minimum the tumour levels throughout the course of treatment was found to produce more regular treatments, at the expense of imposing a higher strain on the patient’s health, and reducing the diversity of the solutions. Moreover, when the number of cycles was incorporated in the problem encoding, and a parsimony pressure added to the objective function, shorter treatments were obtained than those initially found by trial and error.

[1]  Nikolaus Hansen,et al.  Completely Derandomized Self-Adaptation in Evolution Strategies , 2001, Evolutionary Computation.

[2]  L T Chuang,et al.  Effect of new investigational drug taxol on oncolytic activity and stimulation of human lymphocytes , 1993, Gynecologic oncology.

[3]  T. Wheldon Mathematical models in cancer research , 1988 .

[4]  Kenneth A. De Jong,et al.  Measurement of Population Diversity , 2001, Artificial Evolution.

[5]  Ami Radunskaya,et al.  A mathematical tumor model with immune resistance and drug therapy: an optimal control approach , 2001 .

[6]  John A. W. McCall,et al.  Optimising Cancer Chemotherapy Using Particle Swarm Optimisation and Genetic Algorithms , 2004, PPSN.

[7]  Ami Radunskaya,et al.  A delay differential equation model for tumor growth , 2003, Journal of mathematical biology.

[8]  Wainer Zoli,et al.  In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers , 1995, Breast Cancer Research and Treatment.

[9]  D. Browne Clinics in anaesthesiology, volume 2, number 1 , 2004, Intensive Care Medicine.

[10]  Rein Luus,et al.  Iterative dynamic programming , 2019, Iterative Dynamic Programming.

[11]  John A. Adam,et al.  A mathematical model of cycle-specific chemotherapy , 1995 .

[12]  John A. W. McCall,et al.  Multi-objective Optimisation of Cancer Chemotherapy Using Evolutionary Algorithms , 2001, EMO.

[13]  Siddhartha Shakya,et al.  Optimising cancer chemotherapy using an estimation of distribution algorithm and genetic algorithms , 2006, GECCO '06.

[14]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[15]  John Webster,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics, 8th ed , 1992 .

[16]  Ami Radunskaya,et al.  The dynamics of an optimally controlled tumor model: A case study , 2003 .

[17]  Nikolaus Hansen,et al.  Adapting arbitrary normal mutation distributions in evolution strategies: the covariance matrix adaptation , 1996, Proceedings of IEEE International Conference on Evolutionary Computation.

[18]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[19]  Gabriela Ochoa,et al.  Heuristic design of cancer chemotherapies , 2004, IEEE Transactions on Evolutionary Computation.